Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

Nienke M Scheltema; Xynthia M Kavelaars; Kentigern Thorburn; Marije P Hennus; Job B van Woensel; Cornelis K van der Ent; José A M Borghans; Louis J Bont; Julia Drylewicz

doi:10.1016/j.vaccine.2018.06.021

Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

Nienke M Scheltema, Xynthia M Kavelaars, Kentigern Thorburn, Marije P Hennus, Job B van Woensel, Cornelis K van der Ent, José A M Borghans, Louis J Bont, Julia Drylewicz

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.

METHODS: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.

RESULTS: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.

CONCLUSIONS: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.

Original language	English
Pages (from-to)	4693-4700
Number of pages	8
Journal	Vaccine
Volume	36
Issue number	31
DOIs	https://doi.org/10.1016/j.vaccine.2018.06.021
Publication status	Published - 25 Jul 2018

Keywords

Infant mortality
Life-threatening infections
Maternal vaccination
Mathematical model
RSV

Access to Document

10.1016/j.vaccine.2018.06.021

1-s2.0-S0264410X18308375-mainFinal published version, 1.72 MBLicence: CC BY-NC-ND

Cite this

@article{424101e0cfc04b2584d9a6e890156dfd,

title = "Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy",

abstract = "BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.METHODS: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.RESULTS: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.CONCLUSIONS: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.",

keywords = "Infant mortality, Life-threatening infections, Maternal vaccination, Mathematical model, RSV",

author = "Scheltema, {Nienke M} and Kavelaars, {Xynthia M} and Kentigern Thorburn and Hennus, {Marije P} and {van Woensel}, {Job B} and {van der Ent}, {Cornelis K} and Borghans, {Jos{\'e} A M} and Bont, {Louis J} and Julia Drylewicz",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s)",

year = "2018",

month = jul,

day = "25",

doi = "10.1016/j.vaccine.2018.06.021",

language = "English",

volume = "36",

pages = "4693--4700",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "31",

}

TY - JOUR

T1 - Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

AU - Scheltema, Nienke M

AU - Kavelaars, Xynthia M

AU - Thorburn, Kentigern

AU - Hennus, Marije P

AU - van Woensel, Job B

AU - van der Ent, Cornelis K

AU - Borghans, José A M

AU - Bont, Louis J

AU - Drylewicz, Julia

PY - 2018/7/25

Y1 - 2018/7/25

N2 - BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.METHODS: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.RESULTS: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.CONCLUSIONS: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.

AB - BACKGROUND: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants.METHODS: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide.RESULTS: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks' gestational age could have prevented 62-75% of RSV-related PICU admissions in the United Kingdom and 76-87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29-48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children.CONCLUSIONS: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.

KW - Infant mortality

KW - Life-threatening infections

KW - Maternal vaccination

KW - Mathematical model

KW - RSV

U2 - 10.1016/j.vaccine.2018.06.021

DO - 10.1016/j.vaccine.2018.06.021

M3 - Article

C2 - 29941327

SN - 0264-410X

VL - 36

SP - 4693

EP - 4700

JO - Vaccine

JF - Vaccine

IS - 31

ER -

Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy

Abstract

Keywords

Access to Document

Fingerprint

Cite this